Spago Nanomedical Q3 loss narrows 30% to SEK 4.38 million

Bitget2026/11/05 07:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Spago Nanomedical’s third-quarter loss narrowed 30% to SEK 4.38 million; net sales fell to nil.
Operating expenses fell 37% to SEK 4.77 million, while quarter-end cash and cash equivalents more than doubled to SEK 24.52 million.
The board seeks delisting from Nasdaq First North Growth Market to improve Tumorad financing prospects, subject to shareholder approval.
Tumorad-01 reached its maximum tolerated dose endpoint; a planned phase IIa study will focus on head and neck cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spago Nanomedical AB published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Spago Nanomedical Q3 loss narrows 30% to SEK 4.38 million

You may also like

Crypto prices